Biogen Inc (BIIB)
223.18
-3.32
(-1.46%)
USD |
NASDAQ |
Jun 25, 16:00
223.22
+0.04
(+0.02%)
After-Hours: 20:00
Biogen Research and Development Expense (Annual): 2.462B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.462B |
| December 31, 2022 | 2.231B |
| December 31, 2021 | 2.501B |
| December 31, 2020 | 3.991B |
| December 31, 2019 | 2.281B |
| December 31, 2018 | 2.597B |
| December 31, 2017 | 2.254B |
| December 31, 2016 | 1.973B |
| December 31, 2015 | 2.013B |
| December 31, 2014 | 1.893B |
| December 31, 2013 | 1.444B |
| December 31, 2012 | 1.335B |
| December 31, 2011 | 1.220B |
| December 31, 2010 | 1.249B |
| December 31, 2009 | 1.283B |
| Date | Value |
|---|---|
| December 31, 2008 | 1.072B |
| December 31, 2007 | 925.16M |
| December 31, 2006 | 718.39M |
| December 31, 2005 | 747.67M |
| December 31, 2004 | 685.87M |
| December 31, 2003 | 1.056B |
| December 31, 2002 | 100.87M |
| December 31, 2001 | 314.56M |
| December 31, 2000 | 302.84M |
| December 31, 1999 | 221.15M |
| December 31, 1998 | 177.23M |
| December 31, 1997 | 145.50M |
| December 31, 1996 | 132.38M |
| December 31, 1995 | 87.45M |
| December 31, 1994 | 91.21M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.231B
Minimum
2022
3.991B
Maximum
2020
2.693B
Average
2.462B
Median
2023
Research and Development Expense (Annual) Benchmarks
| Ionis Pharmaceuticals Inc | 899.62M |
| Eli Lilly and Co | 9.313B |
| Bristol-Myers Squibb Co | 9.299B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| PTC Therapeutics Inc | 666.56M |